AbCellera Biologics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AbCellera Biologics Inc. (ABCL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.29M, a 14.72% decline year-over-year.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $12.01M, a 19.85% decline year-over-year.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.01M, a 18.39% decline year-over-year.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $14.41M, a 18.98% decline year-over-year.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $56.28M, a 16.72% decline from fiscal 2024.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $67.58M, a 5.29% increase from fiscal 2023.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $64.18M, a 29.71% increase from fiscal 2022.
- AbCellera Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $49.48M, a 69.22% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.29M 10-Q · filed 2026-08-05 | $24.30M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $12.01M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $56.28M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $14.01M 10-Q · filed 2025-11-06 | $28.41M derived: sum of 2 quarters · filed 2026-08-05 | $43.40M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $14.41M 10-Q · filed 2026-08-05 | $29.39M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $14.99M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $67.58M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $17.16M 10-Q · filed 2025-11-06 | $34.95M derived: sum of 2 quarters · filed 2025-11-06 | $52.35M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $17.78M 10-Q · filed 2025-11-06 | $35.19M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $17.41M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $64.18M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $15.86M 10-Q · filed 2024-11-04 | $32.26M derived: sum of 2 quarters · filed 2024-11-04 | $47.73M derived: sum of 3 quarters · filed 2024-11-04 | |
| 2023-06-30 | $16.40M 10-Q · filed 2024-11-04 | $31.87M derived: sum of 2 quarters · filed 2024-11-04 | ||
| 2023-03-31 | $15.47M 10-Q · filed 2024-11-04 | |||
| 2022-12-31 | $49.48M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $11.75M 10-Q · filed 2023-11-02 | $23.87M derived: sum of 2 quarters · filed 2023-11-02 | $36.16M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $12.11M 10-Q · filed 2023-11-02 | $24.40M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $12.29M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $29.24M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $7.71M 10-Q · filed 2022-11-08 | $16.18M derived: sum of 2 quarters · filed 2022-11-08 | $20.20M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $8.47M 10-Q · filed 2022-11-08 | $12.49M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $4.02M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $4.13M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $56.00K 10-Q · filed 2021-11-10 | $520.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.26M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $464.00K 10-Q · filed 2021-11-10 | $1.21M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $744.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $840.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |